Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.39 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2946772 | 0.92 | ALDH1A1 (0.48) | ALDH1A1HSD17B10LMNATSHRSMN1; SMN2 | |
| SCHEMBL2397840 | 0.92 | ALDH1A1 (0.47) | ALDH1A1HSD17B10LMNATSHRSMN1; SMN2 | |
| SCHEMBL22558178 | 0.89 | ALDH1A1 (0.45) | ALDH1A1HSD17B10LMNATSHRSMN1; SMN2 | |
| SCHEMBL8742043 | 0.89 | ALDH1A1 (0.45) | ALDH1A1HSD17B10LMNATSHRSMN1; SMN2 | |
| SCHEMBL8669971 | 0.87 | ALDH1A1 (0.43) | ALDH1A1HSD17B10LMNATSHRSMN1; SMN2 | |
| SCHEMBL27241877 | 0.87 | ALDH1A1 (0.43) | ALDH1A1HSD17B10LMNATSHRSMN1; SMN2 | |
| SCHEMBL27556512 | 0.87 | ALDH1A1 (0.43) | ALDH1A1HSD17B10LMNATSHRSMN1; SMN2 | |
| SCHEMBL27884437 | 0.86 | ALDH1A1 (0.65) | ALDH1A1HSD17B10LMNATSHRSMN1; SMN2 | |
| SCHEMBL27599358 | 0.85 | ALDH1A1 (0.41) | ALDH1A1HSD17B10LMNATSHRSMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL27331677 | 0.85 | ALDH1A1 (0.41) | ALDH1A1HSD17B10LMNATSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020132057-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ANHYDRIDE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION (US) | 2020-06-25 | — | — | WO | claimed |
| US-20200203711-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ANHYDRIDE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2020-06-25 | — | — | US | claimed |
| US-11837711-B2 | Silicon-based energy storage devices with anhydride containing electrolyte additives | ENEVATE CORPORATION (US) | 2023-12-05 | — | — | US | disclosed |
| US-11837711-B2 | Silicon-based energy storage devices with anhydride containing electrolyte additives | ENEVATE CORPORATION (US) | 2023-12-05 | — | — | US | disclosed |
| CN-110337442-B | Novel glucose derivatives as inhibitors of sodium-dependent glucose transporter type 2 | 东亚ST株式会社 | 2023-05-12 | — | — | CN | disclosed |
| US-20210167361-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ANHYDRIDE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2021-06-03 | — | — | US | disclosed |
| US-10957898-B2 | Silicon-based energy storage devices with anhydride containing electrolyte additives | ENEVATE CORPORATION (US) | 2021-03-23 | — | — | US | disclosed |
| WO-2020242253-A1 | NOVEL EMPAGLIFLOZIN DERIVATIVE WHICH IS SGLT-2 INHIBITOR | 동아에스티 주식회사 | 2020-12-03 | — | — | WO | disclosed |
| WO-2020132057-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ANHYDRIDE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200203711-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ANHYDRIDE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2020-06-25 | — | — | US | disclosed |
| US-10682419-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20160263234-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9315542-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9309283-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| EP-2869820-A2 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | Onyx Therapeutics, Inc. (US) | 2015-05-13 | — | — | EP | disclosed |
| US-20140105921-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | ONYX THERAPEUTICS, INC. | 2014-04-17 | — | — | US | disclosed |
| US-20140100154-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | ONYX THERAPEUTICS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-20140100168-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | ONYX THERAPEUTICS, INC. | 2014-04-10 | — | — | US | disclosed |
| WO-2014011695-A2 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20120058232-A1 | Method for the preparation of diacetyl tartaric acid esters of mono-and di-glycerides | LIU GAOFENG (CN) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140105921-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | PREP, VIP, PEPD | ALDH1A1 1285/4885HSD17B10 493/4885LMNA 1138/4885 |
| US-20140100168-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | PREP, VIP, PEPD | ALDH1A1 1285/4885HSD17B10 493/4885LMNA 1138/4885 |
| US-20160263234-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, VIP, PEPD | ALDH1A1 1285/4885HSD17B10 493/4885LMNA 1138/4885 |
| US-20140100154-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | PREP, VIP, PEPD | ALDH1A1 1285/4885HSD17B10 493/4885LMNA 1138/4885 |
| US-10682419-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | PREP, VIP, PEPD | ALDH1A1 1285/4885HSD17B10 493/4885LMNA 1138/4885 |
| US-20120058232-A1 | Method for the preparation of diacetyl tartaric acid esters of mono-and di-glycerides | DGAT2, DGAT1, DGKA | ALDH1A1 1964/4885HSD17B10 242/4885LMNA 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.